Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Serrano, César; Mariño‐Enríquez, Adrián; L. Tao, Derrick; Ketzer, Julia; Eilers, Grant; Zhu, Mei‐Jun; Yu, Channing; M. Mannan, Aristotle; P. Rubin, Brian; D. Demetri, George; P. Raut, Chandrajit; Presnell, Ajia; McKinley, Arin; C. Heinrich, Michael; T. Czaplinski, Jeffrey; Sicińska, Ewa; Bauer, Sebastian; George, Suzanne; A. Fletcher, Jonathan

doi:10.1038/s41416-019-0389-6

Public

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Published in British Journal of Cancer • Feb 21, 2019

Authors:

César Serrano

Adrián Mariño‐Enríquez

Derrick L. Tao

Abstract

BACKGROUND: Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations. Once resistance emerges, targeting KIT with tyrosine kinase inhibitors (TKIs) sunitinib a...

Subject

Regorafenib

Sunitinib

Imatinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!